2 Trump beaten stocks that look like good opportunities for my stocks and ISA stocks

Ever since the election of Donald Trump, investors have been busy trying to separate the winners from the losers. As a result, some stocks and sectors have sold off, which I think has opened up two potentially very profitable opportunities for my Stocks and Shares ISA.

Uber

First of all Uber Technologies (NYSE: UBER). Shares of the bull-eating bull are down 7% since the election.

This follows reports that Trump wants to relax autonomous vehicle (AV) regulations, which will benefit Tesla‘s desires of the robotaxi network. This is a potential risk to Uber’s business model, but one that I think is still years away.

Elon Musk has mentioned 2026/2027 to start producing AVs. However, rival Waymo already does more than 150,000 driverless taxi rides per week, and will also benefit from the relaxation of AV regulations.

Next year, Waymo will expand its robot service to Austin and Atlanta, exclusively for the Uber program. Meanwhile, many other leading AV firms have also signed partnerships with Uber, which now has 161m monthly active platform users.

Wall Street expects Uber’s revenue to continue to grow by double digits in the future, with profits rising significantly.

We continue to develop our autonomous strategy, showing how Uber can help open up this exciting technology to the world.

Uber CEO Dara Khosrowshahi, Q3 2024

The price/earnings-growth (PEG) ratio, based on projected earnings for the next 12 months, is 0.7. Anything less than 1 suggests that the growth stock is undervalued.

As such, I would add to my holdings in Uber if weakness persists.

Novo Nordisk

The following is Novo Nordisk (NYSE: NVO). This is the pharmacy giant in the background Ozempicwhich cures type 2 diabetes and helps to lose weight, too Govyspecifically approved for controlling obesity. Both are known as GLP-1 receptor agonists.

Novo stock is down about 7% since the election and down 30% since June. This latest slide is due to Trump’s nomination of Robert F Kennedy Jr to be the next US health secretary.

As well as being a fan of vaccinations, he is not a fan of weight loss drugs. Instead, he thinks the government should promote healthy eating.

The danger here is that his potential appointment prevents these expensive treatments from being covered by Medicare (currently not for obesity). That would close the door to the US market.

Now, I support campaigns for healthy eating and dealing with harmful processed foods. But 74% of Americans are currently overweight or obese according to government statistics. Unfortunately, I doubt that a healthy diet is enough in most of these situations. Effective treatments are needed, and Novo Nordisk is the global leader in GLP-1 anti-obesity therapies, with a 65% market share.

In Q3, Govy sales are down 81% year over year. And it was recently introduced in China, where about 180m people live with obesity.

Although the product is priced much lower than in the US, it still represents a huge market opportunity. According to a report from JP Morganthese GLP-1 drugs may also eventually treat heart and kidney disease, alcoholism, osteoarthritis, and even Alzheimer’s disease. A drug that can be a real miracle!

After recent declines, the stock trades at 26 times earnings by 2025. For a company that leads the global market for anti-obesity drugs, that valuation seems very attractive.

I have a list of applicants for my ISA in December and this one is near the top.